行情

BLCM

BLCM

Bellicum制药
NASDAQ

实时行情|Nasdaq Last Sale

0.8974
-0.0640
-6.66%
盘后: 0.8965 -0.0009 -0.10% 16:13 12/13 EST
开盘
0.9800
昨收
0.9614
最高
1.010
最低
0.8880
成交量
95.77万
成交额
--
52周最高
4.140
52周最低
0.7211
市值
4,480.24万
市盈率(TTM)
-0.3671
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLCM 新闻

  • 小摩CEO:对种族主义感到“厌恶” 公司仍需改进
  • 新浪美股.42分钟前
  • 收盘:关注贸易关系进展 纳指标普创新高
  • 新浪美股.1小时前
  • 因为用了这三个词 “版权狂魔”迪士尼被告了
  • 新浪美股.2小时前
  • 美国众议院司法委员会投票通过特朗普弹劾指控
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.07%

热门股票

名称
价格
涨跌幅

BLCM 简况

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
展开

Webull提供Bellicum Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。